Gamma-irradiation induces HER-2/neu overexpression in breast cancer cell lines and sensitivity to treatment with trastuzumab

References

• Ahmed KM, Li JJ. 2008. NF-kappa B-mediated adaptive resistance to ionizing radiation. Free Radical Biology & Medicine 44:1–13.
   PubMed Web of Science ®Google Scholar
• Alimandi M, Romano A, Curia MC, Muraro R, Fedi P, Aaronson SA, Di Fiore PP, Kraus MH. 1995. Cooperative signaling of ErbB3 and ErbB2 in neoplastic transformation and human mammary carcinomas. Oncogene 10:1813–1821.
   PubMed Web of Science ®Google Scholar
• Cao N, Li S, Wang Z, Ahmed KM, Degnan ME, Fan M, Dynlacht JR, Li JJ. 2009. NF-kappaB-mediated HER2 overexpression in radiation-adaptive resistance. Radiation Research 171:9–21.
   PubMed Web of Science ®Google Scholar
• Carson WE, Parihar R, Lindemann MJ, Personeni N, Dierksheide J, Meropol NJ, Baselga J, Caligiuri MA. 2001. Interleukin-2 enhances the natural killer cell response to Herceptin-coated Her2/neu-positive breast cancer cells. European Journal of Immunology 31:3016–3025.
   PubMed Web of Science ®Google Scholar
• Clynes RA, Towers TL, Presta LG, Ravetch JV. 2000. Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nature Medicine 6:443–446.
   PubMed Web of Science ®Google Scholar
• Holbro T, Beerli RR, Maurer F, Koziczak M, Barbas CF, Hynes NE. 2003. The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation. Proceedings of the National Academy of Sciences 100:8933–8938.
   PubMed Web of Science ®Google Scholar
• Jones KL, Buzdar AU. 2009. Evolving novel anti-HER2 strategies. The Lancet Oncology 10:1179–1187.
   PubMed Web of Science ®Google Scholar
• Kaufman PA, Broadwater G, Lezon-Geyda K, Dressler LG, Berry D, Friedman P, Winer EP, Hudis C, Ellis MJ, Seidman AD, Harris LN. 2007. CALGB 150002: Correlation of HER2 and chromosome 17 (ch17) copy number with trastuzumab (T) efficacy in CALGB 9840, paclitaxel (P) with or without T in HER2 + and HER2- metastatic breast cancer (MBC). Journal of Clinical Oncology, ASCO Annual Meeting Proceedings 25:1009.
   Google Scholar
• Mittendorf EA, Storrer CE, Shriver CD, Ponniah S, Peoples GE. 2006. Investigating the combination of trastuzumab and HER2/neu peptide vaccines for the treatment of breast cancer. Annals of Surgical Oncology 13:1085–1098.
   PubMed Web of Science ®Google Scholar
• Nahta R, Esteva FJ. 2003. HER-2-targeted therapy: Lessons learned and future directions. Clinical Cancer Research 9:5078–5084.
   PubMed Web of Science ®Google Scholar
• Pegram MD, Finn RS, Arzoo K, Beryt M, Pietras RJ, Slamon DJ. 1997. The effect of HER-2/neu overexpression on chemotherapeutic drug sensitivity in human breast and ovarian cancer cells. Oncogene 15:537–547.
   PubMed Web of Science ®Google Scholar
• Reits EA, Hodge JW, Herberts CA, Groothuis TA, Chakraborty M, Wansley EK, Camphausen K, Luiten RM, de Ru AH, Neijssen J. 2006. Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy. The Journal of Experimental Medicine 203:1259–1271.
   PubMed Web of Science ®Google Scholar
• Schieven GL, Kirihara JM, Myers DE, Ledbetter JA, Uckun FM. 1993. Reactive oxygen intermediates activate NF-kappa B in a tyrosine kinase-dependent mechanism and in combination with vanadate activate the p56lck and p59fyn tyrosine kinases in human lymphocytes. Blood 82:1212–1220.
   PubMed Web of Science ®Google Scholar
• Siegel PM, Ryan ED, Cardiff RD, Muller WJ. 1999. Elevated expression of activated forms of Neu/ErbB-2 and ErbB-3 are involved in the induction of mammary tumors in transgenic mice: Implications for human breast cancer. The EMBO Journal 18:2149–2164.
   PubMed Web of Science ®Google Scholar
• Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. 1987. Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235: 177–182.
   PubMed Web of Science ®Google Scholar
• Sotiriadou NN, Perez SA, Gritzapis AD, Mahaira LG, Salagianni M, Baxevanis CN, Papamichail M. 2005. Beneficial effect of short-term exposure of human NK cells to IL15/IL12 and IL15/IL18 on cell apoptosis and function. Cellular Immunology 234:67–75.
   Google Scholar
• Spector NL, Blackwell KL. 2009. Understanding the mechanisms behind trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer. Journal of Clinical Oncology 27:5838–5847.
   PubMed Web of Science ®Google Scholar
• Tan M, Yao J, Yu D. 1997. Overexpression of the c-erbB-2 gene enhanced intrinsic metastasis potential in human breast cancer cells without increasing their transformation abilities. Cancer Research 57: 1199–1205.
   PubMed Web of Science ®Google Scholar
• Vranic S, Teruya B, Repertinger S, Ulmer P, Hagenkord J, Gatalica Z. 2011. Assessment of HER2 gene status in breast carcinomas with polysomy of chromosome 17. Cancer 117:48–53.
   PubMed Web of Science ®Google Scholar
• Zitvogel L, Apetoh L, Ghiringhelli F, Kroemer G. 2008. Immunological aspects of cancer chemotherapy. Nature Reviews. Immunology 8:59–73.
   Google Scholar